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The astrocytoma cancer represents CNS neoplasms in
which the predominant cell type is derived from an
immortalized astrocyte. The genomewide analysis of
glioma identified somatic mutation at codon 132 of the
IDH1 gene which encodes NADP+ dependent isocitrate
dehydrogenase. Further studies indicated that patients
with somatic, heterozygous R132H mutation have dis-
tinct clinical characteristic: younger age at astrocytoma
diagnosis (WHO II and WHO III) and improved clinical
prognosis. Location of the majority of point mutations in
the IDH1 gene are localized at 132 codon - what simpli-
fies the use of this mutation for potential diagnostic
purposes.
The presence of R132H IDH1 mutation was analysed
in group of 38 patients diagnosed with: fibrillar astrocy-
toma, astrocytoma gemistocyticum, astrocytoma pilocyti-
cum and astrocytoma anaplasticum. The IDH1 mutation
status was determinated by immunohistochemistry using
monoclonal antibody specific for the R132H mutation.
Additional data verification was performed by HRM
Cold-PCR and Sanger sequencing. For statistical evalua-
tion we distinguished two subgroups of patients: with
and without IDH1 R132H mutation. Presence of IDH1
mutation in Polish astrocytomas’ patients correlates with
better clinical outcome and longer median overall survi-
val. Our findings confirm overall tendency for better sur-
vival benefits in patients with IDH1 mutated tumors and
indicates that presence or absence of IDH1 mutant pro-
teins may become a potential target in personalized
medicine.
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